Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• DeSantisCSiegelRBandiPJemalABreast cancer statisticsCA Cancer J Clin201161640941821969133
   PubMed Web of Science ®Google Scholar
• PerouCMSørlieTEisenMBMolecular portraits of human breast tumoursNature2000406679774775210963602
   PubMed Web of Science ®Google Scholar
• SørlieTPerouCMTibshiraniRGene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProc Natl Acad Sci U S A20019819108691087411553815
   PubMed Web of Science ®Google Scholar
• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• SlamonDJGodolphinWJonesLAStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience198924449057077122470152
   PubMed Web of Science ®Google Scholar
• SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20113441178379211248153
   PubMedGoogle Scholar
• RomondEHPerezEABryantJTrastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerN Engl J Med2005353161673168416236738
   PubMed Web of Science ®Google Scholar
• Piccart-GebhartMJProcterMLeyland-JonesBTrastuzumab after adjuvant chemotherapy in HER2-positive breast cancerN Engl J Med2005353161659167216236737
   PubMed Web of Science ®Google Scholar
• MusolinoACiccolalloLPanebiancoMMultifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry studyCancer201111791837184621509760
   PubMed Web of Science ®Google Scholar
• GeyerCEForsterJLindquistDLapatinib plus capecitabine for HER2-positive advanced breast cancerN Engl J Med2006355262733274317192538
   PubMed Web of Science ®Google Scholar
• VogelCChanAGrilBManagement of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinibJpn J Clin Oncol20104011999101320542996
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol200220371972611821453
   PubMed Web of Science ®Google Scholar
• BaselgaJCarbonellXCastañeda-SotoNJPhase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly scheduleJ Clin Oncol200523102162217115800309
   PubMed Web of Science ®Google Scholar
• CobleighMAVogelCLTripathyDMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol19991792639264810561337
   PubMed Web of Science ®Google Scholar
• TripathyDCapecitabine in combination with novel targeted agents in the management of metastatic breast cancer: underlying rationale and results of clinical trialsOncologist200712437538917470680
   PubMed Web of Science ®Google Scholar
• MartyMCognettiFMaraninchiDRandomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupJ Clin Oncol200523194265427415911866
   PubMed Web of Science ®Google Scholar
• MichalakiVFotiouSGennatasSGennatasCTrastuzumab plus capecitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II resultsAnticancer Res20103073051305420683054
   PubMed Web of Science ®Google Scholar
• WardleyAMPivotXMorales-VasquezFRandomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancerJ Clin Oncol20102897698320038734
   PubMed Web of Science ®Google Scholar
• ValeroVForbesJPegramMDMulticenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimensJ Clin Oncol201129214915621115860
   PubMed Web of Science ®Google Scholar
• MoulderSLiHWangMA phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group TrialBreast Cancer Res Treat2010119366367120012354
   PubMed Web of Science ®Google Scholar
• UntchMMuschollMTjulandinSFirst-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trialJ Clin Oncol20102891473148020177030
   PubMed Web of Science ®Google Scholar
• RobertNLeyland-JonesBAsmarLRandomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancerJ Clin Oncol200624182786279216782917
   PubMed Web of Science ®Google Scholar
• YardleyDABurrisHA3rdSimonsLA phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancerClin Breast Cancer20088542543118952556
   PubMed Web of Science ®Google Scholar
• AnderssonMLidbrinkEBjerreKPhase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA studyJ Clin Oncol201129326427121149659
   PubMed Web of Science ®Google Scholar
• KaufmanBMackeyJRClemensMRTrastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM studyJ Clin Oncol200927335529553719786670
   PubMed Web of Science ®Google Scholar
• Von MinckwitzGdu BoisASchmidtMTrastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 studyJ Clin Oncol200927121999200619289619
   PubMed Web of Science ®Google Scholar
• Von MinckwitzGSchwedlerKSchmidtMTrastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3–05 phase III study in HER2-positive breast cancerEur J Cancer201147152273228121741829
   PubMed Web of Science ®Google Scholar
• GelmonKAMackeyJVermaSUse of trastuzumab beyond disease progression: observations from a retrospective review of case historiesClin Breast Cancer2004515258 discussion 59–6215140285
   PubMedGoogle Scholar
• FabiAMetroGFerrettiGDo HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studiesBreast200817549950518450443
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med2011365141273128321991949
   PubMed Web of Science ®Google Scholar
• PerezEARomondEHSumanVJFour-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31J Clin Oncol201129253366337321768458
   PubMed Web of Science ®Google Scholar
• FerrettiGFabiAFeliciAPapaldoPImproved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative diseaseJ Clin Oncol20102820e337 author reply e338–e33920479395
   PubMed Web of Science ®Google Scholar
• UntchMFaschingPAKonecnyGEPathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groupsJ Clin Oncol201129253351335721788566
   PubMed Web of Science ®Google Scholar
• BuzdarAUIbrahimNKFrancisDSignificantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerJ Clin Oncol200523163676368515738535
   PubMed Web of Science ®Google Scholar
• GianniLEiermannWSemiglazovVNeoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLancet2010375971237738420113825
   PubMed Web of Science ®Google Scholar
• UntchMRezaiMLoiblSNeoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro studyJ Clin Oncol201028122024203120308670
   PubMed Web of Science ®Google Scholar
• SuterTMCook-BrunsNBartonCCardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancerBreast200413317318315177418
   PubMed Web of Science ®Google Scholar
• SuterTMProcterMvan VeldhuisenDJTrastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant trialJ Clin Oncol200725253859386517646669
   PubMed Web of Science ®Google Scholar
• PerezEASumanVJDavidsonNECardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trialJ Clin Oncol20082681231123818250349
   PubMed Web of Science ®Google Scholar
• CostaRBKurraGGreenbergLGeyerCEEfficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancerAnn Oncol201021112153216020351072
   PubMed Web of Science ®Google Scholar
• CallahanRHurvitzSHuman epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent diseaseCurr Opin Obstet Gynecol2011231374321500375
   PubMed Web of Science ®Google Scholar
• ScaltritiMRojoFOcañaAExpression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancerJ Natl Cancer Inst200799862863817440164
   PubMed Web of Science ®Google Scholar
• KöstlerWJSchwabBSingerCFMonitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancerClin Cancer Res20041051618162415014012
   PubMed Web of Science ®Google Scholar
• LuYZiXZhaoYMascarenhasDPollakMInsulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)J Natl Cancer Inst200193241852185711752009
   PubMed Web of Science ®Google Scholar
• HarrisLNYouFSchnittSJPredictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancerClin Cancer Res20071341198120717317830
   PubMed Web of Science ®Google Scholar
• RitterCAPerez-TorresMRinehartCHuman breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor networkClin Cancer Res200713164909491917699871
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell20046211712715324695
   PubMed Web of Science ®Google Scholar
• O’BrienNABrowneBCChowLActivated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinibMol Cancer Ther2010961489150220501798
   PubMed Web of Science ®Google Scholar
• BernsKHorlingsHMHennessyBTA functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancerCancer Cell200712439540217936563
   PubMed Web of Science ®Google Scholar
• StemmlerHJKahlertSSiekieraWCharacteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancerBreast200615221922516026983
   PubMed Web of Science ®Google Scholar
• ClaytonAJDansonSJollySIncidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancerBr J Cancer200491463964315266327
   PubMed Web of Science ®Google Scholar
• BendellJCDomchekSMBursteinHJCentral nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaCancer200397122972297712784331
   PubMed Web of Science ®Google Scholar
• DawoodSBroglioKEstevaFJDefining prognosis for women with breast cancer and CNS metastases by HER2 statusAnn Oncol20081971242124818334512
   PubMed Web of Science ®Google Scholar
• StemmlerJSchmittMWillemsABernhardHHarbeckNHeinemannVBrain metastases in HER2-overexpressing metastatic breast cancer: comparative analysis of trastuzumab levels in serum and cerebrospinal fluidJ Clin Oncol20062418S1525
   Google Scholar
• ParkYHParkMJJiSHTrastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patientsBr J Cancer2009100689490019240719
   PubMed Web of Science ®Google Scholar
• ParkIHRoJLeeKSNamBHKwonYShinKHTrastuzumab treatment beyond brain progression in HER2-positive metastatic breast cancerAnn Oncol2009201566218664558
   PubMed Web of Science ®Google Scholar
• XiaWMullinRJKeithBRAnti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathwaysOncogene200221416255626312214266
   PubMed Web of Science ®Google Scholar
• KonecnyGEPegramMDVenkatesanNActivity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsCancer Res20066631630163916452222
   PubMed Web of Science ®Google Scholar
• NahtaRYuanLXDuYEstevaFJLapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signalingMol Cancer Ther20076266767417308062
   PubMed Web of Science ®Google Scholar
• XiaWHusainILiuLLapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancersCancer Res20076731170117517283152
   PubMed Web of Science ®Google Scholar
• XiaWGerardCMLiuLBaudsonNMOryTLSpectorNLCombining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cellsOncogene200524416213622116091755
   PubMed Web of Science ®Google Scholar
• ScaltritiMVermaCGuzmanMLapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicityOncogene200928680381419060928
   PubMed Web of Science ®Google Scholar
• ChuIBlackwellKChenSSlingerlandJThe dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancerCancer Res2005651182515665275
   PubMed Web of Science ®Google Scholar
• EmdeAMMaslakKLiuHRelesAEPossingerKEuckerJCombination of fulvestrant and lapatinib in non-HER2-overexpressing and adriamycin-resistant breast cancer cell linesJ Clin Oncol20072518S14050
   Google Scholar
• BurrisHA3rdHurwitzHIDeesECPhase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomasJ Clin Oncol200523235305531315955900
   PubMed Web of Science ®Google Scholar
• BursteinHJStornioloAMFrancoSA phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancerAnn Oncol20081961068107418283035
   PubMed Web of Science ®Google Scholar
• BlackwellKLPegramMDTan-ChiuESingle-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimensAnn Oncol20092061026103119179558
   PubMed Web of Science ®Google Scholar
• ToiMIwataHFujiwaraYLapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studiesBr J Cancer2009101101676168219844234
   PubMed Web of Science ®Google Scholar
• GomezHLDovalDCChavezMAEfficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancerJ Clin Oncol200826182999300518458039
   PubMed Web of Science ®Google Scholar
• StornioloAMPegramMDOvermoyerBPhase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancerJ Clin Oncol200826203317332318490651
   PubMed Web of Science ®Google Scholar
• BlackwellKLBursteinHJStornioloAMRandomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancerJ Clin Oncol20102871124113020124187
   PubMed Web of Science ®Google Scholar
• BlackwellKBursteinHSledgeGUpdated survival a nalysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapyCancer Res20096924 Suppl 361
   Web of Science ®Google Scholar
• JohnstonSPippenJJrPivotXLapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerJ Clin Oncol200927335538554619786658
   PubMed Web of Science ®Google Scholar
• CortésJSauraCBelletMHER2 and hormone receptor-positive breast cancer: blocking the right targetNat Rev Clin Oncol20118530731121151204
   PubMed Web of Science ®Google Scholar
• YenLYouXLAl MoustafaAEHeregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesisOncogene200019313460346910918604
   PubMed Web of Science ®Google Scholar
• PetitAMRakJHungMCNeutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumorsAm J Pathol19971516152315309403702
   PubMed Web of Science ®Google Scholar
• KonecnyGEMengYGUntchMAssociation between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patientsClin Cancer Res20041051706171615014023
   PubMed Web of Science ®Google Scholar
• EpsteinMAyalaRTchekmedyianNBorgstromPPegramMSlamonDHER2-overexpressing human breast cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VEGF)Presented at San Antonio Breast Cancer Symposium2002 Abstract 570
   Google Scholar
• RugoHSJo Chien AFrancoSXA phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancerBreast Cancer Res Treat Epub12 242011
   Web of Science ®Google Scholar
• SlamonDGomezHLKabbinavarFFRandomized study of pazopanib + lapatinib vs lapatinib alone in patients with HER2-positive advanced or metastatic breast cancerJ Clin Oncol200826 Suppl abstract 1016
   PubMedGoogle Scholar
• CameronDCaseyMPressMA phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analysesBreast Cancer Res Treat2008112353354318188694
   PubMed Web of Science ®Google Scholar
• CameronDCaseyMOlivaCNewstatBImwalleBGeyerCELapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trialOncologist201015992493420736298
   PubMed Web of Science ®Google Scholar
• Di LeoAGomezHLAzizZPhase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancerJ Clin Oncol200826345544555218955454
   PubMed Web of Science ®Google Scholar
• CastañedaCAGomezHLTargeted therapies: combined lapatinib and paclitaxel in HER2-positive breast cancerNat Rev Clin Oncol20096630830919483734
   PubMedGoogle Scholar
• LoRussoPMJonesSFKochKMPhase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancerJ Clin Oncol200826183051305618565892
   PubMed Web of Science ®Google Scholar
• GajriaDGonzalezJFeiginKPhase II trial of a novel capecitabine dosing schedule in combination with l apatinib for the treatment of patients with HER2-positive metastatic breast cancerBreast Cancer Res Treat2012131111111621898114
   PubMed Web of Science ®Google Scholar
• ChewHKSomloGMackPCPhase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumorsAnn Oncol2001 Epub7 21
   Google Scholar
• DecensiAPuntoniMPruneriGLapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trialCancer Prev Res (Phila)2011481181118921685235
   PubMed Web of Science ®Google Scholar
• JohnstonSTrudeauMKaufmanBPhase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapyJ Clin Oncol20082671066107218212337
   PubMed Web of Science ®Google Scholar
• BoussenHCristofanilliMZaksTDeSilvioMSalazarVSpectorNPhase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancerJ Clin Oncol201028203248325520530274
   PubMed Web of Science ®Google Scholar
• DaveBMigliaccioIGutierrezMCLoss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancersJ Clin Oncol201129216617321135276
   PubMed Web of Science ®Google Scholar
• HolmesFANagarwalaYMEspinaVACorrelation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapyJ Clin Oncol201129 Suppl abstract 506
   PubMedGoogle Scholar
• UntchMLoiblSBischoffJArbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGO-B) Study GroupLapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trialLancet Oncol201213213514422257523
   PubMed Web of Science ®Google Scholar
• Von MinckwitzGEidtmannHLoiblSIntegrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trialAnn Oncol201122230130620624784
   PubMed Web of Science ®Google Scholar
• BaselgaJBradburyIEidtmannHNeoALTTO Study TeamLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialLancet2012379981663364022257673
   PubMed Web of Science ®Google Scholar
• KaklamaniVGSiziopikouKScholtensDPilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinibBreast Cancer Res Treat2011 Epub2 27
   PubMed Web of Science ®Google Scholar
• ParkIHLeeKSKangHSA phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancerInvest New Drugs2011 Epub10 18
   Web of Science ®Google Scholar
• LinNUWinerEPBrain metastases: the HER2 paradigmClin Cancer Res20071361648165517363517
   PubMed Web of Science ®Google Scholar
• LinNUBellonJRWinerEPCNS metastases in breast cancerJ Clin Oncol200422173608361715337811
   PubMed Web of Science ®Google Scholar
• PalmieriDBronderJLHerringJMHer-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brainCancer Res20076794190419817483330
   PubMed Web of Science ®Google Scholar
• GrilBPalmieriDBronderJLEffect of lapatinib on the outgrowth of metastatic breast cancer cells to the brainJ Natl Cancer Inst2008100151092110318664652
   PubMedGoogle Scholar
• LinNUDiérasVPaulDMulticenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancerClin Cancer Res20091541452145919228746
   PubMed Web of Science ®Google Scholar
• BoccardoFKaufmanBBaselgaJEvaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d’Utilisation (ATU)J Clin Oncol20082615S1094
   Google Scholar
• MetroGFogliettaJRussilloMClinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabineAnn Oncol201122362563020724575
   PubMed Web of Science ®Google Scholar
• BartschRBerghoffAPluschnigUImpact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastasesBr J Cancer20121061253122127284
   PubMed Web of Science ®Google Scholar
• LinNUEiermanWGreilRRandomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastasesJ Neurooncol2011105361362021706359
   PubMed Web of Science ®Google Scholar
• SchwartzbergLSFrancoSXFloranceAO’RourkeLMaltzmanJJohnstonSLapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancerOncologist201015212212920156908
   PubMed Web of Science ®Google Scholar
• MoyBGossPELapatinib-associated toxicity and practical management recommendationsOncologist200712775676517673607
   PubMed Web of Science ®Google Scholar
• PerezEAKoehlerMByrneJPrestonAJRappoldEEwerMSCardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trialsMayo Clin Proc200883667968618533085
   PubMed Web of Science ®Google Scholar
• WuYAmonkarMMSherrillBHImpact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancerAnn Oncol201122122582259021406472
   PubMed Web of Science ®Google Scholar
• ZhouXCellaDCameronDLapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessmentBreast Cancer Res Treat2009117357758919153829
   PubMed Web of Science ®Google Scholar
• SherrillBDi LeoAAmonkarMMQuality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancerCurr Med Res Opin201026476777520095796
   PubMed Web of Science ®Google Scholar